Denali Therapeutics CFO Steve Krognes to join Board; COO Alex Schuth adds CFO role effective May 1, 2022

Denali Therapeutics Inc.

Krognes transitions from CFO to Class III director as of May 1, 2022; his term expires at 2023 annual meeting.
Alexander Schuth, current COO and Secretary, becomes Chief Operating and Financial Officer on May 1, 2022.
No changes to Schuth's compensation in connection with his expanded role; Krognes to receive standard board cash and equity.
Krognes cited a personal desire to move back to Europe; Watts and Board expressed gratitude and support for continuity.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Alexander Schuth

Chief Operating and Financial Officer

DNLI · Denali Therapeutics Inc.

Effective: 2022-05-01
Filed: March 16, 2022, 7:59 PM ET

Alexander Schuth, M.D., current Chief Operating Officer and Secretary of the Company, will add the Chief Financial Officer role to his current responsibilities, becoming Denali’s Chief Operating and Financial Officer.

Departed

Steve Krognes

Chief Financial Officer

DNLI · Denali Therapeutics Inc.

Effective: 2022-05-01
Successor: Alexander Schuth
Filed: March 16, 2022, 7:59 PM ET

Steve Krognes will transition from his role as Chief Financial Officer to join the Company’s Board of Directors as of May 1, 2022

Appointed

Steve Krognes

Director

DNLI · Denali Therapeutics Inc.

Effective: 2022-05-01
Filed: March 16, 2022, 7:59 PM ET

On March 14, 2022, Mr. Krognes was appointed to the Board, effective May 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexander Schuth was appointed as Chief Operating and Financial Officer at Denali Therapeutics Inc..

Action: appointed
Role: Chief Operating and Financial Officer

Exact text from the filing

Alexander Schuth, M.D., current Chief Operating Officer and Secretary of the Company, will add the Chief Financial Officer role to his current responsibilities, becoming Denali’s Chief Operating and Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Steve Krognes changed role as Chief Financial Officer at Denali Therapeutics Inc..

Action: transitioned
Role: Chief Financial Officer

Exact text from the filing

Steve Krognes will transition from his role as Chief Financial Officer to join the Company’s Board of Directors as of May 1, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Steve Krognes was appointed as Director at Denali Therapeutics Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 14, 2022, Mr. Krognes was appointed to the Board, effective May 1, 2022.

View on SEC.gov

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-077264

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.